K

Kancera AB
F:3EE0

Watchlist Manager
Kancera AB
F:3EE0
Watchlist
Price: 0.0001 EUR Market Closed
Market Cap: 12.1k EUR

Operating Margin
Kancera AB

0%
Current
0%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-34.5m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Kancera AB
STO:KAN
19.4m SEK N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
402.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
178.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.1B USD
28%
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54B USD
8%
NL
argenx SE
XBRU:ARGX
44.4B EUR
22%
No Stocks Found

Kancera AB
Glance View

Market Cap
12.1k EUR
Industry
Biotechnology

Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.

3EE0 Intrinsic Value
0.0001 EUR
Undervaluation 13%
Intrinsic Value
Price
K
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-34.5m
/
Revenue
0
What is the Operating Margin of Kancera AB?

Based on Kancera AB's most recent financial statements, the company has Operating Margin of 0%.

Back to Top